Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience
Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience
复制标题
DOI：
10.1159/000477792
复制
发表时间：
2017-01-01
影响因子：
2.4
通讯作者：
Nomura, Shosaku
中科院分区：
文献类型：
--
作者：
Nakaya, Aya;Fujita, Shinya;Nomura, Shosaku
来那度胺是一种口服免疫调节药物，用于治疗多发性骨髓瘤。由于合并症和/或不良事件，一些老年患者需要减少来那度胺剂量。这项研究调查了老年患者来那度胺的实际剂量，发现大多数患者接受了减少的剂量（5-10 毫克）。减少剂量的最常见原因是肾功能不全（54%的患者）、疲劳（≥3级；20%）、血液系统疾病（≥3级；14%）和皮疹（≥3级；9%）。他们的中位进展时间为 11.8 个月，中位总生存期为 39.2 个月。总体缓解率为73%，其中完全缓解为17%，部分缓解非常好为19%，部分缓解为37%。这些结果表明，与西方国家相反，大多数患者在日本接受了减少剂量的来那度胺治疗。然而，建议以可耐受剂量继续治疗可能会产生良好的结果。 (C) 2017 作者由 S. Karger AG 出版，巴塞尔
Lenalidomide is an immunomodulatory drug administered orally in the treatment of multiple myeloma. Some elderly patients require a reduced lenalidomide dose because of comorbidities and/or adverse events. This study investigated the actual dose of lenalidomide in elderly patients, finding that most received reduced (5-10 mg) doses. The most common reasons for dose reduction were renal dysfunction (54% of patients), fatigue (grade >= 3; 20%), hematologic disorder (grade >= 3; 14%), and rash (grade >= 3; 9%). Their median time to progression was 11.8 months and their median overall survival was 39.2 months. The overall response rate was 73%, including 17% with a complete response, 19% with a very good partial response, and 37% with a partial response. These results showed that, contrary to western countries, most patients were treated with a reduced dose of lenalidomide in Japan. However, it is suggested that continued treatment with a tolerable dose may yield favorable outcomes. (C) 2017 The Author(s) Published by S. Karger AG, Basel